Despite the widespread skepticism over renal denervation for hypertension after the failure of Medtronic's Symplicity-3 trial, St. Jude Medical could be poised to snatch victory from the jaws of defeat with its next-generation EnligHTN device.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1vqeusX
Cap comentari:
Publica un comentari a l'entrada